The Intercepting Blood Cancers Workshop (IBC) 2027 will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:

• Lymphoma, chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL)
• Multiple myeloma, smoldering myeloma (SMM) and monoclonal gammopathy of unknown significance (MGUS)
• Clonal hematopoiesis of indeterminate potential (CHIP), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and clonal cytopenia of undetermined significance (CCUS)

 

IBC 2026 took place in person between 19–21 March 2026 in Barcelona, Spain.